C4 therapeutics reports second quarter 2025 financial results and recent business highlights

Cemsidomide phase 1 data in multiple myeloma accepted as an oral presentation  at the international myeloma society (ims) annual meeting; as of the july 23, 2025, data cutoff, phase 1 orr remains at 40% at the 75 Μg dose level and at 50% at the 100 Μg dose level productive type c meeting held with fda; registrational development of cemsidomide in multiple myeloma on track to initiate in early 2026 preclinical milestone achieved under the collaboration with merck kgaa, darmstadt, germany, which is focused on two projects within the kras family   disciplined capital allocation extends runway to mid-2027 watertown, mass., aug. 07, 2025 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the second quarter ended june 30, 2025, as well as business updates.
CCCC Ratings Summary
CCCC Quant Ranking